2023
DOI: 10.1016/j.str.2022.11.008
|View full text |Cite
|
Sign up to set email alerts
|

Structures of drug-specific monoclonal antibodies bound to opioids and nicotine reveal a common mode of binding

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
4
2

Relationship

1
5

Authors

Journals

citations
Cited by 10 publications
(2 citation statements)
references
References 42 publications
0
2
0
Order By: Relevance
“…Notably, additional crystal structures of fentanyl-bound mAbs were published during this article’s revision process. 61 The crystals reveal important differences related to the residues involved in ligand binding, the overall topology of the antibody-ligand interaction (we observe an approximately 180° inversion in docking mode relative to the published models), and the conformational changes involved in ligand binding (identified through the combination of the crystallography and ITC-based thermodynamics). We hypothesize that this conformational change that “traps” the fentanyl is key to high affinity and subsequent protection.…”
Section: Discussionmentioning
confidence: 77%
“…Notably, additional crystal structures of fentanyl-bound mAbs were published during this article’s revision process. 61 The crystals reveal important differences related to the residues involved in ligand binding, the overall topology of the antibody-ligand interaction (we observe an approximately 180° inversion in docking mode relative to the published models), and the conformational changes involved in ligand binding (identified through the combination of the crystallography and ITC-based thermodynamics). We hypothesize that this conformational change that “traps” the fentanyl is key to high affinity and subsequent protection.…”
Section: Discussionmentioning
confidence: 77%
“…Additionally, some high-affinity drugs have functional groups branching from the center N that may clash with CDR H2 in the bound C10-S66K structure, but the binding observed in Table 1 suggests that CDR H2 should be able to adopt different conformations to accommodate them (Figure 4). In contrast, other published antibodies like HY6-F9, 24 FenAb609, 12 and FenAb208 12 have binding pockets that interact with unique functional groups of fentanyl, making them unlikely to bind to fentanyl analogs. Therefore, C10-S66K represents a promising candidate for antibody therapeutics that recognize fentanyl, carfentanil, and related drugs that share the core phenylethyl and piperidinyl group.…”
mentioning
confidence: 99%